Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1436 - 1436
Опубликована: Дек. 20, 2024
The
concept
of
"platform
technology"
gained
prominence
after
the
Ebola
outbreak
and
since
then
has
become
essential
to
international
vaccine
(prophylactic
vaccines
against
infectious
disease)
regulatory
frameworks.
Its
significance
was
further
amplified
during
COVID-19
pandemic,
where
platform
technology
enabled
rapid
development
approval
vaccines,
optimizing
processes,
enhancing
global
public
health
responses.
As
a
transformative
tool,
streamlines
product
development,
allowing
for
reduction
in
number
clinical
trials
or
exemption
from
certain
facilitating
cross-referencing
submissions.
Despite
significant
efforts
establish
standardized
procedures,
challenges
remain,
particularly
achieving
unified
definition
application
across
regions.
This
paper
explores
evolution,
applications,
strategies
technology,
with
focus
on
China's
experience
this
field.
approach,
encompassing
risk
assessment,
expedited
emergency
offers
valuable
insights
into
coordination.
By
analyzing
contributions
practices,
highlights
potential
address
future
pandemics,
including
"Pathogen
X",
underscores
importance
harmonizing
strengthen
preparedness
response.
Nucleic
acid
therapeutics
represent
a
highly
promising
treatment
approach
in
modern
medicine,
treating
diseases
at
the
genetic
level.
However,
these
face
numerous
challenges
practical
applications,
particularly
regarding
their
stability,
effectiveness,
cellular
uptake
efficiency,
and
limitations
delivering
them
specifically
to
target
tissues.
To
overcome
obstacles,
researchers
have
developed
various
innovative
delivery
systems,
including
viral
vectors,
lipid
nanoparticles,
polymer
inorganic
protein
carriers,
exosomes,
antibody
oligonucleotide
conjugates,
DNA
nanostructure-based
systems.
These
systems
enhance
therapeutic
efficacy
of
nucleic
drugs
by
improving
targeting
specificity,
half-life
vivo.
In
this
review,
we
systematically
discuss
different
types
drugs,
analyze
major
barriers
encountered
delivery,
summarize
current
research
progress
emerging
We
also
highlight
latest
advancements
application
for
diseases,
infectious
cancer,
brain
wound
healing.
This
review
aims
provide
comprehensive
overview
drug
systems'
status
future
directions
integrating
nanotechnology,
biomaterials
science,
gene
editing
technologies,
emphasizing
transformative
potential
precision
medicine.
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Апрель 6, 2025
Abstract
Borrelia
burgdorferi
(
Bb
)
causes
Lyme
disease
(LD),
one
of
the
most
common
vector-borne
diseases
in
Northern
Hemisphere.
Here,
we
solve
crystal
structure
a
mutated
vaccine
antigen,
CspZ-YA
that
lacks
ability
to
bind
host
complement
factor
H
(FH).
We
generate
point
mutants
and
identify
I183Y
C187S
trigger
more
robust
bactericidal
responses.
Compared
CspZ-YA,
these
require
lower
immunization
frequency
protect
mice
from
LD-associated
inflammation
bacterial
colonization.
Antigenicity
wild-type
mutant
proteins
are
similar,
as
measured
using
sera
infected
people
or
immunized
female
mice.
Structural
comparison
with
shows
enhanced
interactions
two
helices
adjacent
FH-binding
sites
mutants,
consistent
their
elevated
thermostability.
In
line
findings,
protective
monoclonal
antibodies
show
increased
binding
at
physiological
temperature
(37
°C).
summary,
this
proof-of-concept
study
applies
structural
vaccinology
enhance
intramolecular
for
long-term
stability
antigen
while
maintaining
its
epitopes,
thus
promoting
LD
development.
Advanced Functional Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 9, 2025
Abstract
Gene
therapy
has
brought
hope
for
curing
major
diseases
including
cancer.
However,
an
efficient
and
safe
delivery
system
is
key
successful
gene
therapy.
In
this
study,
PPERD
(i.e.,
OHC‐PEG‐CHO/PEtOx
0.2
‐PEI
0.73
‐PRGD
0.07
/DNA),
polyoxazoline‐based
developed
to
mediate
tumor
vascular
normalization
extracellular
matrix
(ECM)
degradation
cancer
The
aldehyde
groups
of
OHC‐PEG‐CHO
can
form
Schiff
base
bonds
with
the
amine
PER
PEtOx
),
thereby
enabling
in
situ
encapsulation
PERD
PER/DNA)
rapid
pH
responsiveness
tissues.
possesses
excellent
vitro
transfection
performance
good
biocompatibility.
efficiently
accumulate,
penetrate,
transfect
tumors
once
intravenous
administration.
effectively
normalizes
vasculature
degradates
ECM,
enhances
infiltration
function
cytotoxic
T
lymphocytes,
inducing
antitumor
immune
response
vivo.
Moreover,
PPERVH
((i.e.,
/(pshVEGF+pHAase))
also
inhibit
recurrence
metastasis
by
triggering
durable
anti‐tumor
memory
effect.
Furthermore,
significantly
effectiveness
checkpoint
blockade‐mediated
immunotherapy.
This
strategy
provides
a
promising
paradigm
inhibiting
growth,
recurrence,
metastasis.
Science Translational Medicine,
Год журнала:
2025,
Номер
17(794)
Опубликована: Апрель 16, 2025
Artificial
intelligence
(AI)
has
already
transformed
vaccine
antigen
design
and
could
transform
the
entire
vaccinology
pipeline,
including
immune
responses
emerging
infectious
disease
prediction,
manufacturing
regulatory
processes,
clinical
trial
implementation,
access
equity.
However,
realizing
promise
of
AI
for
requires
more
high-quality
data.
Salud Ciencia y Tecnología,
Год журнала:
2025,
Номер
4
Опубликована: Янв. 15, 2025
Introduction:
The
integration
of
artificial
intelligence
(AI)
into
vaccine
development
has
revolutionized
traditional
methodologies,
significantly
enhancing
the
speed,
precision,
and
scalability
immunological
research.
Emerging
re-emerging
infectious
diseases,
driven
by
zoonotic
spillovers,
antimicrobial
resistance,
global
environmental
changes,
pose
substantial
challenges.
Addressing
these
requires
innovative
approaches,
with
AI
playing
a
pivotal
role
in
advancing
solutions.Development:
applications
vaccinology
include
antigen
detection,
adjuvant
optimization,
immune
response
simulation.
Deep
learning
algorithms
streamline
identification
immunogenic
targets
conserved
antigens,
enabling
for
highly
mutable
pathogens
such
as
SARS-CoV-2,
HIV,
influenza.
Case
studies
demonstrate
AI's
transformative
impact,
including
its
rapid
creation
mRNA
vaccines
COVID-19,
promising
antigens
malaria,
enhanced
efficacy
influenza
through
predictive
modeling.
However,
challenges
unequal
access
to
technology,
biases
data
models,
ethical
concerns
regarding
genomic
privacy
persist.
Recommendations
address
barriers
increasing
diversity,
strengthening
frameworks,
investing
infrastructure
democratize
AI-driven
innovations.Conclusions:
ability
reduce
time
cost,
improve
enable
personalized
immunization
strategies
positions
it
cornerstone
modern
vaccinology.
With
continued
advancements
equitable
implementation,
holds
potential
reshape
development,
pandemic
preparedness,
longstanding
public
health
disparities
globally.
